Pacira Joins PROBE Consortium to Advance Osteoarthritis Research with Data from 70 Million Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2025
0mins
Should l Buy PCRX?
Source: Newsfilter
- Collaborative Innovation: Pacira Biosciences has joined the PROBE Consortium, leveraging data from 70 million patients to improve osteoarthritis (OA) research and treatment, thereby enhancing global patient care quality.
- Data-Driven Approach: The consortium will utilize AI models to predict disease progression, which not only supports personalized medicine but also addresses data fragmentation issues in OA research, thus driving innovation in treatment evaluation.
- Multi-Stakeholder Collaboration: The PROBE Consortium brings together 38 partners from academia, industry, patient organizations, and regulatory agencies, forming a robust cross-sector collaboration network to tackle significant challenges in the OA field and improve clinical care outcomes.
- Strategic Objectives: By contributing data from the ASCEND study, Pacira demonstrates its leadership in non-opioid pain therapies, aiming to meet the urgent needs of OA patients globally and drive therapeutic innovation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PCRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PCRX
Wall Street analysts forecast PCRX stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 21.450
Low
23.00
Averages
30.33
High
38.00
Current: 21.450
Low
23.00
Averages
30.33
High
38.00
About PCRX
Pacira BioSciences, Inc. is the holding company for its subsidiary, Pacira Pharmaceuticals, Inc. The Company has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
San Francisco Expands Free Childcare Access, Saving Families Thousands Annually
- Income Support for Families: San Francisco's plan provides free childcare for children under five to families earning less than $230,000, while those earning up to $310,000 qualify for partial subsidies, potentially saving families tens of thousands of dollars annually.
- Addressing Living Costs: The initiative targets childcare costs that can reach $30,000 annually for full-time infant care, with city officials stating that this move offers meaningful economic relief for middle-class families, helping them remain in the city.
- Funding Assurance: Funding for the initiative will come from a commercial rent tax approved by voters in 2018, with estimates suggesting that unused revenue will support approximately 20,000 children through 2032, ensuring the program's sustainability.
- Political Context: Mayor Daniel Lurie, as part of a growing group of Democratic leaders, is pushing this affordability agenda, reflecting a broader focus on the economic pressures facing middle-class families post-2024 election cycle, with similar efforts underway in New York.
See More
Pacira BioSciences Partners with LG Chem to Expand Access to EXPAREL in Asia-Pacific Markets
- Market Expansion Partnership: Pacira BioSciences has entered into an agreement with LG Chem, granting exclusive rights to commercialize EXPAREL in Asia-Pacific markets, aiming to enhance patient access to opioid-sparing postsurgical pain management, aligning with global trends to reduce opioid dependency.
- Financial Benefit Structure: Under the terms of the deal, Pacira will receive an undisclosed upfront payment, a transfer price, and tiered royalties on future commercial sales by LG Chem, providing a stable revenue stream and enhancing financial flexibility for Pacira.
- Market Authorization Plans: LG Chem intends to file for marketing authorizations for EXPAREL in South Korea and Thailand within the next six months, a move that will not only expedite product availability but also strengthen Pacira's market position in the Asia-Pacific region.
- Stock Market Reaction: Following the announcement, Pacira's stock price rose by 0.87% to $23.13 in pre-market trading on Nasdaq, reflecting positive market sentiment towards the partnership and potentially driving future growth prospects for the company.
See More
Rich Sparkle Holdings Signs $39 Million Share Offering Agreement
- Stock Surge: Rich Sparkle Holdings Ltd's shares skyrocketed 115% to $52.00 following the signing of a $39 million agreement for 3 million ordinary shares, indicating strong market confidence in its financing strategy.
- Positive Market Reaction: The offering price of $13 per share is significantly lower than the current market price, reflecting optimistic investor expectations regarding the company's growth potential, which may provide essential funding for future expansions.
- Significant Industry Impact: The successful financing of Rich Sparkle Holdings not only enhances its market position but could also attract more investor attention to the sector, potentially driving up stock prices of related companies.
- Optimistic Future Outlook: With the influx of capital, the company is poised to accelerate its business development and market expansion, further solidifying its competitive advantage in the industry.
See More
Pacira BioSciences to Present at 44th Annual J.P. Morgan Healthcare Conference
- Conference Presentation: Pacira BioSciences will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 11:15 AM PST, aiming to reinforce its leadership in innovative non-opioid pain therapies.
- Live Access: The live audio of the event will be accessible via the company’s website under the “Events” section, allowing investors and healthcare professionals to stay updated on the latest developments.
- Replay Availability: A replay of the webcast will be available for two weeks post-event, ensuring that stakeholders who cannot attend live can still access critical information, thereby enhancing transparency.
- Product Line Overview: Pacira currently markets three commercial-stage non-opioid treatments, including EXPAREL, ZILRETTA, and iovera®, and the successful promotion of these products will further solidify the company's competitive edge in the pain management market.
See More
PharmaCorp Grants 501,088 Options at $0.46 with 10-Year Expiry
- Options Grant: PharmaCorp has granted a total of 501,088 options to directors, officers, employees, and consultants at an exercise price of $0.46, which is expected to enhance employee motivation and improve overall operational efficiency.
- Regulatory Compliance: The options grant relies on exemptions under MI 61-101, avoiding formal valuation requirements and ensuring compliance on the TSXV, thereby reducing administrative costs.
- Shareholder Protection: The options granted do not exceed 25% of the company's market capitalization, thus avoiding the need for minority approval under MI 61-101, which ensures efficient decision-making.
- Strategic Development Focus: As a pharmacy acquisition platform, PharmaCorp aims to build a national network of community pharmacies through capital and strategic support, and the options grant will further attract talent to drive its expansion plans.
See More
PharmaCorp Grants 501,088 Options at $0.46 Exercise Price
- Options Grant: PharmaCorp has granted a total of 501,088 options to directors, officers, employees, and consultants at an exercise price of $0.46, expiring on December 31, 2035, indicating the company's commitment to incentivizing its team.
- Regulatory Compliance: The company relied on provisions of MI 61-101 to exempt the formal valuation requirements for the options granted to directors and officers, ensuring compliance while reducing administrative burdens.
- Capital Structure Optimization: The options granted do not exceed 25% of the company's market capitalization, reflecting a strategy to enhance internal incentive mechanisms while safeguarding shareholder interests.
- Strategic Development Focus: As a pharmacy acquisition platform, PharmaCorp aims to build a national network of community pharmacies through capital and strategic support, further solidifying its competitive position in the market.
See More
San Francisco Expands Free Childcare Access, Saving Families Thousands Annually
- Income Support for Families: San Francisco's plan provides free childcare for children under five to families earning less than $230,000, while those earning up to $310,000 qualify for partial subsidies, potentially saving families tens of thousands of dollars annually.
- Addressing Living Costs: The initiative targets childcare costs that can reach $30,000 annually for full-time infant care, with city officials stating that this move offers meaningful economic relief for middle-class families, helping them remain in the city.
- Funding Assurance: Funding for the initiative will come from a commercial rent tax approved by voters in 2018, with estimates suggesting that unused revenue will support approximately 20,000 children through 2032, ensuring the program's sustainability.
- Political Context: Mayor Daniel Lurie, as part of a growing group of Democratic leaders, is pushing this affordability agenda, reflecting a broader focus on the economic pressures facing middle-class families post-2024 election cycle, with similar efforts underway in New York.
See More
Pacira BioSciences Partners with LG Chem to Expand Access to EXPAREL in Asia-Pacific Markets
- Market Expansion Partnership: Pacira BioSciences has entered into an agreement with LG Chem, granting exclusive rights to commercialize EXPAREL in Asia-Pacific markets, aiming to enhance patient access to opioid-sparing postsurgical pain management, aligning with global trends to reduce opioid dependency.
- Financial Benefit Structure: Under the terms of the deal, Pacira will receive an undisclosed upfront payment, a transfer price, and tiered royalties on future commercial sales by LG Chem, providing a stable revenue stream and enhancing financial flexibility for Pacira.
- Market Authorization Plans: LG Chem intends to file for marketing authorizations for EXPAREL in South Korea and Thailand within the next six months, a move that will not only expedite product availability but also strengthen Pacira's market position in the Asia-Pacific region.
- Stock Market Reaction: Following the announcement, Pacira's stock price rose by 0.87% to $23.13 in pre-market trading on Nasdaq, reflecting positive market sentiment towards the partnership and potentially driving future growth prospects for the company.
See More
Rich Sparkle Holdings Signs $39 Million Share Offering Agreement
- Stock Surge: Rich Sparkle Holdings Ltd's shares skyrocketed 115% to $52.00 following the signing of a $39 million agreement for 3 million ordinary shares, indicating strong market confidence in its financing strategy.
- Positive Market Reaction: The offering price of $13 per share is significantly lower than the current market price, reflecting optimistic investor expectations regarding the company's growth potential, which may provide essential funding for future expansions.
- Significant Industry Impact: The successful financing of Rich Sparkle Holdings not only enhances its market position but could also attract more investor attention to the sector, potentially driving up stock prices of related companies.
- Optimistic Future Outlook: With the influx of capital, the company is poised to accelerate its business development and market expansion, further solidifying its competitive advantage in the industry.
See More
Pacira BioSciences to Present at 44th Annual J.P. Morgan Healthcare Conference
- Conference Presentation: Pacira BioSciences will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 11:15 AM PST, aiming to reinforce its leadership in innovative non-opioid pain therapies.
- Live Access: The live audio of the event will be accessible via the company’s website under the “Events” section, allowing investors and healthcare professionals to stay updated on the latest developments.
- Replay Availability: A replay of the webcast will be available for two weeks post-event, ensuring that stakeholders who cannot attend live can still access critical information, thereby enhancing transparency.
- Product Line Overview: Pacira currently markets three commercial-stage non-opioid treatments, including EXPAREL, ZILRETTA, and iovera®, and the successful promotion of these products will further solidify the company's competitive edge in the pain management market.
See More
PharmaCorp Grants 501,088 Options at $0.46 with 10-Year Expiry
- Options Grant: PharmaCorp has granted a total of 501,088 options to directors, officers, employees, and consultants at an exercise price of $0.46, which is expected to enhance employee motivation and improve overall operational efficiency.
- Regulatory Compliance: The options grant relies on exemptions under MI 61-101, avoiding formal valuation requirements and ensuring compliance on the TSXV, thereby reducing administrative costs.
- Shareholder Protection: The options granted do not exceed 25% of the company's market capitalization, thus avoiding the need for minority approval under MI 61-101, which ensures efficient decision-making.
- Strategic Development Focus: As a pharmacy acquisition platform, PharmaCorp aims to build a national network of community pharmacies through capital and strategic support, and the options grant will further attract talent to drive its expansion plans.
See More
PharmaCorp Grants 501,088 Options at $0.46 Exercise Price
- Options Grant: PharmaCorp has granted a total of 501,088 options to directors, officers, employees, and consultants at an exercise price of $0.46, expiring on December 31, 2035, indicating the company's commitment to incentivizing its team.
- Regulatory Compliance: The company relied on provisions of MI 61-101 to exempt the formal valuation requirements for the options granted to directors and officers, ensuring compliance while reducing administrative burdens.
- Capital Structure Optimization: The options granted do not exceed 25% of the company's market capitalization, reflecting a strategy to enhance internal incentive mechanisms while safeguarding shareholder interests.
- Strategic Development Focus: As a pharmacy acquisition platform, PharmaCorp aims to build a national network of community pharmacies through capital and strategic support, further solidifying its competitive position in the market.
See More
